Skip to main content
. 2023 Apr 3;29(5):1092–1102. doi: 10.1038/s41591-023-02297-5

Extended Data Fig. 1. Antitumor activity of lorlatinib by RECIST response in patients with soft tissue disease.

Extended Data Fig. 1

Bar color represents best overall response for all sites of disease by NANT response criteria v2.0. Dashed line represents 30% change from baseline to obtain PR or greater in soft tissue sector of response, #Soft tissue not involved at enrollment, *Soft tissue became MIBG non-avid.

Source data